SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its first quarter 2018 financial results before the market opens on Wednesday, May 2, 2018.
United Therapeutics will host a teleconference on Wednesday, May 2, 2018, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 5778455.
This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm. [uthr-g]
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Advertisement
United Therapeutics will host a teleconference on Wednesday, May 2, 2018, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 5778455.
Advertisement
This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm. [uthr-g]
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.
View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-first-quarter-2018-financial-results-before-the-market-opens-on-wednesday-may-2-2018-300634871.html
SOURCE United Therapeutics Corporation
